Optimer Pharmaceuticals has announced the approval of Dificid (fidaxomicin) Tablets by the Australian regulatory body, the Therapeutic Goods Administration. Specialised Therapeutics Australia that has license to fidaxomicin in Australia ...
Astellas Pharma Europe, a European subsidiary of Astellas, has introduced Dificlir (generic name: fidaxomicin) tablets in the Europe. Dificlir, indicated to treat Clostridium difficile infections (CDI), is an orally administered, ...
Tags: Dificlir, fidaxomicin, CDI